Free Trial!
Today’s Best Stocks To Trade! Click Here
Nilam Resources Inc. (OTC BB: NILR; http://www.marketwatch.com/quotes/nilr)
Nilam Resources Inc. Announces Plans for Dual Listing on Toronto Stock Exchange Clarification of May 27th Press Release
TORONTO, ONTARIO, Jun 30, 2008 -- Len DeMelt, Chairman of Nilam Resources Inc. states "For clarity, we plan to dual list the company on the TSX, and will not be doing a secondary offering. A dual listing will not dilute the amount of shares that the company has and will eliminate stock dilution.
Nilam Resources Inc. is pleased to announce its plans to engage a financial institution for a dual listing on the Toronto Stock Exchange. The company is currently in discussions with both Canadian and American corporate lawyers who specialize in such dual listings. The Toronto Stock Exchange is the world's premiere exchange for the mining industry. Some 60% of the world's mining companies are listed on the Toronto Stock Exchange. In 2006, over $11 billion was raised for exploration by Toronto Stock Exchange listed companies.
"A dual listing on the Toronto Stock Exchange will dramatically increase our visibility within the investment community and the mining industry as a whole," said Mr. DeMelt.
Emisphere Technologies Inc. (NASDAQ: EMIS; http://www.marketwatch.com/quotes/emis)
Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH) Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women
CEDAR KNOLLS, N.J., June 30, 2008 -- Emisphere Technologies, Inc. announced today that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis. The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34 combined with different amounts of 5-CNAC administered orally. The trial is being conducted in Switzerland and is estimated to yield first interpretable results by the end of the year.
Osteoporosis is a disease associated with a gradual thinning and weakening of the bones, occurring most frequently in women after menopause. Thinner and weaker bones are increasingly susceptible to fractures. Untreated postmenopausal osteoporosis can lead to chronic back pain, disabling fractures, and lost mobility.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its Eligen(R) technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The web site is: www.emisphere.com.
Sympowerco Corporation (Pink Sheets: SYMW; http://www.marketwatch.com/quotes/symw)
SymPowerco Marks Progress on Joint Development Plans
LAS VEGAS, NV, Jun 30, 2008 -- SymPowerco Corporation (PINKSHEETS: SYMW) CEO John Davenport today announces that the company and its development partner, Carleton University of Ottawa, Canada, are completing the 2008/2009 development plans for the company's Flowing Electrolyte Direct Methanol Fuel Cell (FE DMFC).
As previously announced, SymPowerco has partnered with Carleton University to rapidly advance the company's FE DMFC technologies.
Chief among the research initiatives for the 2008/2009 program will be scalability studies to determine the engineering and development path to 50 Watt and 500 Watt FE DMFCs. These studies will include extensive operational testing of SymPowerco's 5 Watt FE DMFC Hybrid Power System using a wide array of operational and structural variables.
Also planned for the 2008/2009 program are advanced materials engineering studies as they relate to the FE DMFC. The complex physical, chemical and electrical processes in an operating FE DMFC coupled with manufacturing and operational economics demand careful selection and extensive testing of the FE DMFC materials of construction.
SymPowerco CEO, John Davenport, commented, "This promises to be an exciting session at Carleton University's Department of Mechanical and Aerospace Engineering. This year's program is designed to rapidly advance our Flowing Electrolyte Direct Methanol Fuel Cell technologies and to bring the FE DMFC closer to commercial reality." SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.
Visit, WallStreetGrapevine.com, to read the disclaimer and/ or sign up for our free WSGV Newsletter
CONTACT: WallStreetGrapevine.com Tel: +1 585 454 6950 ext 100 WWW: http://wallstreetgrapevine.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
